On Wednesday, William Blair started covering Zura Bio Limited (ZURA) with an Outperform rating. The reason? Its lead drug candidate, tibulizumab, which the firm believes could be a blockbuster in autoimmune diseases.

Analyst Matt Phipps said the investment thesis hinges on tibulizumab's dual inhibition of key inflammatory pathways that drive both T-cell and B-cell activity. That mechanism, he argues, could produce better outcomes in complex, hard-to-treat autoimmune conditions.

Phase 2 Trials Outpace Enrollment Goals

In June, Zura Bio announced it had completed enrollment in the Phase 2 TibuSHIELD trial testing tibulizumab in adults with hidradenitis suppurativa (HS). The study exceeded its target, enrolling 247 participants. Meanwhile, the Phase 2 TibuSURE trial in adults with early diffuse cutaneous systemic sclerosis (SSc) is on track to finish enrollment in early July and has already surpassed its goal of 80 participants.

Top-line data from TibuSHIELD are expected in the fourth quarter of 2026, with TibuSURE results due in the first half of 2027. Zura also plans to start a Phase 2 trial in a third immune-mediated disease by the end of this year.

Analyst Projects Multibillion-Dollar Sales Potential

Phipps said tibulizumab has the potential to outperform currently approved therapies in both HS and SSc. He estimates peak global sales of $2.3 billion in HS, assuming a 2031 launch, with a current net present value of $8.04 per share.

The analyst also pointed to translational data supporting tibulizumab's mechanism in SSc, noting that autoantibodies and IL-17-driven inflammation play important roles in the disease. While SSc has seen fewer clinical studies than HS, Phipps said positive data from the IL-17 receptor antibody brodalumab and the BAFF-targeting therapy Benlysta provide proof of concept for the dual-pathway approach and support the ongoing TibuSURE study.

William Blair projects peak global SSc sales of $1.6 billion for tibulizumab, with a potential 2031 launch and a current net present value of $4.51 per share.

As of March 31, 2026, Zura Bio held $225.6 million in cash and cash equivalents, which management expects will fund operations through at least the end of 2028.

ZURA Stock Price Activity: Zura Bio shares were up 3.15% at $5.24 at the time of publication on Wednesday, according to market data.